<DOC>
	<DOCNO>NCT02792725</DOCNO>
	<brief_summary>The treat physician/investigator contact Lilly , base medical opinion , patient meet criteria inclusion expand access program .</brief_summary>
	<brief_title>Expanded Access Program Provide Abemaciclib ( LY2835219 ) Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Have diagnosis hormone receptor positive ( HR+ ) , human epidermal growth factor receptor 2 negative ( HER2 ) breast cancer . To fulfill requirement HR+ disease , breast cancer must express , immunohistochemistry , least 1 hormone receptor ( estrogen receptor progesterone receptor ) . To fulfill requirement HER2 disease , breast cancer must demonstrate , initial diagnosis upon subsequent biopsy , overexpression HER2 either immunohistochemistry insitu hybridization . Have recurrent , locally advanced , unresectable metastatic breast cancer disease progression follow antiestrogen therapy . Have performance status 0 2 Eastern Cooperative Oncology Group scale . Have discontinue previous therapy cancer ( include chemotherapy , radiotherapy , immunotherapy , endocrine therapy ) least 21 day myelosuppressive agent 14 day nonmyelosuppressive agent prior receive abemaciclib , recover acute effect therapy ( toxicity resolve either baseline least Grade 1 ) except residual alopecia peripheral neuropathy . Have adequate organ function , include : Hematologic : absolute neutrophil count ≥1.5 × 10⁹/Liter ( L ) , platelets ≥100 × 10⁹/L , hemoglobin ≥8 grams/deciliter . Participants may receive erythrocyte transfusion achieve hemoglobin level discretion treat physician . Initial treatment begin earlier day erythrocyte transfusion . Hepatic : bilirubin ≤1.5 × upper limit normal ( ULN ) alanine aminotransferase ≤3 × ULN . Renal : serum creatinine ≤ULN . If woman childbearing potential , must test negative pregnancy time enrollment base serum pregnancy test , must agree use reliable method birth control program 3 month follow last dose abemaciclib . If man , must agree use reliable method birth control donate sperm program least 3 month follow last dose abemaciclib ( country requirement , whichever long ) . Are able swallow capsule . Are currently enrol clinical trial involve investigational product concurrently enrol type medical research judge scientifically medically compatible program . Have progressive central nervous system metastasis require immediate local therapy include ( limited ) wholebrain radiotherapy , stereotactic radiosurgery , surgical resection , intrathecal chemotherapy . Have history progressive disease prior therapy cyclindependent kinase ( CDK ) 4 &amp; 6 inhibitor . Have major surgery within 14 day initial dose abemaciclib . Have personal history follow condition : syncope either unexplained cardiovascular etiology , ventricular tachycardia , ventricular fibrillation , sudden cardiac arrest . Have active bacterial , fungal , and/or know viral infection . If lactating , must agree begin and/or discontinue breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>